{"analyses":[{"ciLowerLimit":"0.391","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.600","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","paramType":"Hazard Ratio (HR)","paramValue":"0.484","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"18.46","upperLimit":"32.92","value":"22.08"},{"comment":"Here NA signifies that the median, lower limit and upper limit of confidence interval (CI) were not estimable due to lesser number of events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"527"},{"groupId":"OG001","value":"525"}],"units":"Participants"}],"description":"rPFS as assessed by the investigator was defined as the duration from the date of randomization to the date of first documentation of radiographic progressive disease or death due to any cause, whichever occurred first. Radiographic progressive disease was defined as progression of soft tissue lesions measured by computed tomography (CT) or magnetic resonance imaging (MRI) as defined by modified Response evaluation criteria in solid tumors (RECIST) 1.1.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received matching placebo (4 tablets) orally once daily (qd) along with ADT (gonadotropin releasing hormone analog \\[GnRHa\\] or surgical castration) as standard of care therapy in each 28-day treatment cycle. The choice of the GnRHa (agonist or antagonist) was at discretion of the investigator. In the event of a positive result at interim or final analysis participants in treatment phase had opportunity to receive Apalutamide +ADT. Participants received treatment until radiographic progression or unequivocal clinical progression, unacceptable toxicity, or death.","id":"OG000","title":"Placebo + Androgen Deprivation Therapy (ADT)"},{"description":"Participants received JNJ-56021927 (apalutamide) 240 milligrams (mg) (4\\*60 mg tablets) orally qd along with ADT (gonadotropin releasing hormone analog \\[GnRHa\\] or surgical castration) as standard of care therapy in each 28-day treatment cycle. The choice of the GnRHa (agonist or antagonist) was at discretion of the investigator. Participants received treatment until radiographic progression or unequivocal clinical progression, unacceptable toxicity, or death.","id":"OG001","title":"Apalutamide + ADT"}],"paramType":"MEDIAN","populationDescription":"Intent to treat (ITT) population included all randomized participants classified according to their assigned treatment group, regardless of the actual treatment received.","reportingStatus":"POSTED","timeFrame":"Up to 35 months","title":"Radiographic Progression-free Survival (rPFS)","type":"PRIMARY","unitOfMeasure":"months"}